Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|July 8, 2013

Base4 and Hitachi High-Tech Collaborate on Developing Novel Nanopore DNA-Sequencing System

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so.

Base4 Innovation Ltd., a Cambridge-based DNA-sequencing company, and Hitachi High-Technologies Corporation, a technology company developing and manufacturing scientific and medical systems, announced that they have entered into an agreement to develop a long read-length, single-molecule, nanopore-based DNA-sequencing system based on Base4’s technology and Hitachi’s state-of-the-art instrumentation.

The core DNA-sequencing technology is based on the concept of passing a single strand of DNA through a nanometer-scale pore and reading out the sequence directly as it does so. A method was developed by Base4 to increase the signal from the single molecule as it passes through the pore by using laser light enhanced by gold structures. Minimal sample preparation is required and the signal can be read from unlabelled DNA.

The system offers easy analysis of genetic material. It will be able to directly read DNA modifications, such as methylation, which is relevant to the genes associated with cancer, as well as achieve long read lengths.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.